Skip to content
Disclosery

QIMING U.S. VENTURES MANAGEMENT, LLC

Follow

13F filer, CIK 1909617, BELLEVUE, WA

QIMING U.S. VENTURES MANAGEMENT, LLC reported $89,696,050 across 6 holdings for the quarter ended 2024-03-31, in a 13F-HR filed 2024-05-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001104659-24-061168

Period
2024-03-31
Reported value
$89.7M
Holdings
6
Top 10 weight
100%
New
1
Sold out
3

Largest buys vs the previous quarter

SecurityShares changeApprox. value
JSPRnew+928,964$27.3M
Tourmaline Bio Incadded+100,000$2.29M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ICOSAVAX INCexited-3,510,228-$55.3M
JASPER THERAPEUTICS INCexited-8,519,648-$6.72M
VTYXreduced-274,145-$1.51M
ELEVATION ONCOLOGY INC COMexited-2,370,142-$1.27M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2024

Share positions as resolved from 13F-HR 0001104659-24-061168, largest first. % of portfolio is the value over $89,696,050, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
KRROKORRO BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 368,085 shares; 2024Q1: 368,085 shares 368,085$33.1M36.93%0Timeline
JSPRJASPER THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: not reported; 2024Q1: 928,964 shares 928,964$27.3M30.41%newTimeline
Tourmaline Bio IncTourmaline Bio IncQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 641,691 shares; 2024Q1: 741,691 shares 741,691$17M18.94%+100,000
HILLEVAX INCHILLEVAX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 558,923 shares; 2024Q1: 558,923 shares 558,923$9.29M10.36%0
VTYXVENTYX BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 686,370 shares; 2024Q1: 412,225 shares 412,225$2.27M2.53%-274,145Timeline
KEZAR LIFE SCIENCES INCKEZAR LIFE SCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 828,711 shares; 2024Q1: 828,711 shares 828,711$747K0.83%0

Sold out in Q1 2024

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ICOSAVAX INCICOSAVAX INC3,510,228$55.3Mshares
JASPER THERAPEUTICS INCJASPER THERAPEUTICS INC8,519,648$6.72Mshares
ELEVATION ONCOLOGY INC COMELEVATION ONCOLOGY INC COM2,370,142$1.27Mshares

How Q1 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-24-061168 base2024-05-14acceptance time not in the bulk data set